Cargando…

Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma

ABSTRACT: Patients with early-stage lung adenocarcinoma (LUAD) exhibit different overall survival (OS) rates and immunotherapy responses. Understanding the immune landscape facilitates the personalized treatment of LUAD. The immune cell populations in tumour tissues were quantified to depict the imm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bao, Xuanwen, Shi, Run, Zhao, Tianyu, Wang, Yanfang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297823/ https://www.ncbi.nlm.nih.gov/pubmed/32333046 http://dx.doi.org/10.1007/s00109-020-01908-9

Ejemplares similares

Mast cell‐based molecular subtypes and signature associated with clinical outcome in early‐stage lung adenocarcinoma
por: Bao, Xuanwen, et al.
Publicado: (2020)

Development and validation of a hypoxia-related gene signature to predict overall survival in early-stage lung adenocarcinoma patients
por: Sun, Jing, et al.
Publicado: (2020)

Prognostic and Predictive Value of Three DNA Methylation Signatures in Lung Adenocarcinoma
por: Wang, Yanfang, et al.
Publicado: (2019)

A novel 4-gene signature for overall survival prediction in lung adenocarcinoma patients with lymph node metastasis
por: Wang, Yanfang, et al.
Publicado: (2019)

Immune Landscape of Invasive Ductal Carcinoma Tumor Microenvironment Identifies a Prognostic and Immunotherapeutically Relevant Gene Signature
por: Bao, Xuanwen, et al.
Publicado: (2019)

Identification and validation of hypoxia-derived gene signatures to predict clinical outcomes and therapeutic responses in stage I lung adenocarcinoma patients
por: Shi, Run, et al.
Publicado: (2021)

Clinical Significance and Immune Landscape of Recurrence-Associated Ferroptosis Signature in Early-Stage Lung Adenocarcinoma
por: Yi, Lilan, et al.
Publicado: (2022)

A novel epigenetic signature for overall survival prediction in patients with breast cancer
por: Bao, Xuanwen, et al.
Publicado: (2019)

Landscape and dynamics of single tumor and immune cells in early and advanced‐stage lung adenocarcinoma
por: Chen, Zhencong, et al.
Publicado: (2021)

Immune landscape and prognostic immune-related signature in KRAS-mutated lung adenocarcinoma
por: Peng, Xinyi, et al.
Publicado: (2023)

Identification and Application of a Novel Immune-Related lncRNA Signature on the Prognosis and Immunotherapy for Lung Adenocarcinoma
por: Zeng, Zhimin, et al.
Publicado: (2022)

A circular RNAs dataset landscape reveals potential signatures for the detection and prognosis of early-stage lung adenocarcinoma
por: Chen, Zhiying, et al.
Publicado: (2021)

A novel metabolic-immune related signature predicts prognosis and immunotherapy response in lung adenocarcinoma
por: Tang, Xiaolong, et al.
Publicado: (2022)

A novel immune checkpoints-based signature to predict prognosis and response to immunotherapy in lung adenocarcinoma
por: Sun, Nan, et al.
Publicado: (2022)

A novel cuproptosis-related lncRNA signature to predict prognosis and immune landscape of lung adenocarcinoma
por: Wang, Xinyi, et al.
Publicado: (2023)

Immune landscape and a promising immune prognostic model associated with TP53 in early‐stage lung adenocarcinoma
por: Wu, Chengde, et al.
Publicado: (2020)

Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis
por: Zhu, Mingchuang, et al.
Publicado: (2022)

Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma
por: Wu, Pancheng, et al.
Publicado: (2020)

Immune-Related lncRNA Pairs as Prognostic Signature and Immune-Landscape Predictor in Lung Adenocarcinoma
por: Yin, Zhengrong, et al.
Publicado: (2022)

Low GAS5 Levels as a Predictor of Poor Survival in Patients with Lower-Grade Gliomas
por: Wang, Yanfang, et al.
Publicado: (2019)

Corrigendum: Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis
por: Zhu, Mingchuang, et al.
Publicado: (2022)

Identification of Prognostic Genes and Immune Landscape Signatures Based on Tumor Microenvironment in Lung Adenocarcinoma
por: Han, Pengkai, et al.
Publicado: (2022)

Cuproptosis and Immune-Related Gene Signature Predicts Immunotherapy Response and Prognosis in Lung Adenocarcinoma
por: Sun, Zihao, et al.
Publicado: (2023)

Immune microenvironment analysis and novel biomarkers of early-stage lung adenocarcinoma evolution
por: Liu, Jun, et al.
Publicado: (2023)

A more novel and powerful prognostic gene signature of lung adenocarcinoma determined from the immune cell infiltration landscape
por: Ma, Chao, et al.
Publicado: (2022)

Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma
por: Wang, Yuli, et al.
Publicado: (2022)

Identification of a Novel Immune Landscape Signature for Predicting Prognosis and Response of Colon Cancer to Immunotherapy
por: Wang, Zheng, et al.
Publicado: (2022)

Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis
por: Shu, Jianfeng, et al.
Publicado: (2023)

Characterization of the alternative splicing landscape in lung adenocarcinoma reveals novel prognosis signature associated with B cells
por: Shao, Ming-Ming, et al.
Publicado: (2023)

A robust prognostic gene expression signature for early stage lung adenocarcinoma
por: Krzystanek, Marcin, et al.
Publicado: (2016)

High-risk early-stage lung adenocarcinoma patients are identified by an immune-related circadian clock gene signature
por: Wang, Zi-Hao, et al.
Publicado: (2022)

Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma
por: Huang, Ziqi, et al.
Publicado: (2021)

Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma
por: Zeng, Weibiao, et al.
Publicado: (2023)

Comprehensive Analysis of a Novel Immune-Related Gene Signature in Lung Adenocarcinoma
por: Feng, Hongxiang, et al.
Publicado: (2022)

Landscape of Mitochondria Genome and Clinical Outcomes in Stage 1 Lung Adenocarcinoma
por: Raghav, Lovely, et al.
Publicado: (2020)

Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy
por: Shi, Jiawei, et al.
Publicado: (2022)

Deconvolution of malignant pleural effusions immune landscape unravels a novel macrophage signature associated with worse clinical outcome in lung adenocarcinoma patients
por: Bruschini, Sara, et al.
Publicado: (2022)

Identification of lung adenocarcinoma subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genes
por: Hua, Linbin, et al.
Publicado: (2023)

Identification of an Innate Immune-Related Prognostic Signature in Early-Stage Lung Squamous Cell Carcinoma
por: Li, Liang, et al.
Publicado: (2021)

Immune Microenvironment Signatures as Biomarkers to Predict Early Recurrence of Stage Ia-b Lung Cancer
por: Wang, Qiang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_50rk3fvlukjrjra77jo7689495